The Current Gap
Despite advances in the treatment of neurological disease there are no neuroprotective therapies on the market.
Unlocking naturally occurring patient-derived
neuroprotective therapies
THE CHALLENGE
THE SOLUTION
WHAT WE OFFER
Developing neuroprotective agents
GenrAb is harnessing the power of human immunity to develop therapies that can protect and treat patients with neurological diseases. Developing neuroprotective agents will provide patients with the next generation of treatment that can retard the progression of disease and allow for new approaches to their care.
GenrAb’s proprietary Antibody Gene Signature (AGS) technology has identified >400 potentially therapeutic fully-human mAbs to treat neurological disorders. These antibodies leverage naturally created neuroprotective mechanisms found in individuals experiencing neurodegeneration.
WHY WE DO IT
Changing the course of neurological disorders
At GenrAb, we’re driven by the need to fill a crucial gap in neurological care.
We leverage our groundbreaking AGS technology to unlock new possibilities in treatment, looking to transform patient care and offer hope where it’s most needed. We do this not just for scientific advancement but to profoundly impact lives. This is our commitment, our passion, and our promise.
Our mission is simple yet profound: to develop neuroprotective therapies that change the course of neurological disorders and create a future where effective neurological care is a reality for all.
HOW WE DO IT
Unlocking the potential of the human immune system to develop advanced treatments for neurological diseases, providing patients with enhanced protection and innovative care strategies.
Immune-Centric
Drug Discovery
Novel approach to drug discovery that harnesses the power of the human immune system as the source of developing novel therapeutics.
Neuroprotective
Pipeline
Platform in place for drug development of neuroprotective monoclonal antibodies.